New LLM evaluation system for AI drug discovery agents validated by human experts

Researchers have developed a new LLM-based evaluation system to assess the performance of AI agents in drug discovery, addressing the limitations of traditional metrics and the scalability issues of human evaluation. The system, tested with the ChatInvent assistant at AstraZeneca, defines four quality dimensions and uses LLM judges to evaluate outputs. A human alignment study found that Gemini-3.1 Pro, Claude Opus 4.7, GPT-5, and Llama 3.1 70B were evaluated as potential judges, with the best-performing judge optimized using few-shot demonstrations to achieve an 0.86 alignment with human experts. The framework aims to provide a reusable template for evaluating agentic systems in scientific domains. AI

IMPACT This framework offers a scalable and human-aligned method for evaluating complex AI agents in scientific research, potentially accelerating development in drug discovery and other fields.

RANK_REASON The cluster contains an academic paper detailing a new methodology for evaluating AI systems. [lever_c_demoted from research: ic=1 ai=1.0]

Read on arXiv cs.LG →

• arXiv
• AstraZeneca
• ChatInvent
• Claude Opus 4.7
• Gemini-3.1 Pro
• GPT-5
• Llama 3.1 70B

• paper
• product
• safety

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →